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Emilia sonchifolia (L.) DC (Compositae), an herbaceous plant found in Taiwan and India, is used as folk medicine. The clinical
applications include inﬂammation, rheumatism, cough, cuts fever, dysentery, analgesic, and antibacteria. The activities of Emilia
sonchifolia extract (ESE) on colorectal cancer cell death have not been fully investigated. The purpose of this study explored
the induction of apoptosis and its molecular mechanisms in ESE-treated HCT 116 human colorectal cancer cells in vitro.T h e
methanolic ESE was characterized, and γ-humulene was formed as the major constituent (63.86%). ESE induced cell growth
inhibition in a concentration- and time-dependent response by MTT assay. Apoptotic cells (DNA fragmentation, an apoptotic
catachrestic) were found after ESE treatment by TUNEL assay and DNA gel electrophoresis. Alternatively, ESE stimulated the
activities of caspase-3, -8, and -9 and their speciﬁc caspase inhibitors protected against ESE-induced cytotoxicity. ESE promoted
the mitochondria-dependent and death-receptor-associated protein levels. Also, ESE increased ROS production and upregulated
the levels of ATM, p53, and Fas in HCT 116 cells. Strikingly, p53 siRNA reversed ESE-reduced viability involved in p53-mediated
ATM/Fas signaling in HCT 116 cells. In summary, our result is the ﬁrst report suggesting that ESE may be potentially eﬃcacious
in the treatment of colorectal cancer.
1.Introduction
Colorectal cancer is a major reason of death worldwide [1],
and it is the third most frequent cause of cancer death in
Taiwan. About 20.2 per 100,000 people died of colorectal
cancer according to the reports of the Department of Health,
R.O.C. (Taiwan) in 2010 (http://www.doh.gov.tw/EN2006/
index EN.aspx/). Recently, various studies have shown that
traditional Chinese medicine (TCM) and folklore medicine
possessed potential anticolorectal cancer activity and they
are associated with a reduced risk of cancer [2–4]. It
has been reported that the TCM and folklore medicine
can induce reactive oxygen species (ROS) production and
DNA damage, which leads to increased phosphorylation
of ataxia-telangiectasia-mutated kinase (ATM) and p53 and
then triggers apoptosis in human cancer cells [5]. The p532 Evidence-Based Complementary and Alternative Medicine
phosphorylation at the residue of Ser15 in the human
cell line has been linked to apoptosis which is induced
by chemotherapeutic and chemopreventive agents [6]. The
factor of p53 has been recognized as a transcription factor
that transactivates apoptotic target genes such as Fas/CD95,
death receptor 5 (DR5), BH3 interacting domain death ago-
nist (Bid), phorbol-12-myristate-13-acetate-induced protein
1 (PMAIP 1), and Bcl-2 binding component 3 (PUMA)
[6, 7]. On the other hand, upregulated p53 gene expression
has been implicated in both extrinsic and intrinsic apoptotic
signaling pathways [8, 9].
Emilia sonchifolia (L.) DC (Compositae) is a folklore me-
dicinal plant in China and Taiwan. It is used for inﬂam-
mation, rheumatism, inﬂammation, eye sores, convulsion,
cough,cuts,andwounds.Inpreviousstudies,themethanolic
Emilia sonchifolia extract (ESE) exhibited anticancer prop-
erty, anti-inﬂammatory, and antioxidant activity [10]. In
chemical study, it is shown that the Emilia sonchifolia
contains alkaloids, ﬂavonoids, and terpernes, including
γ-humulene, kaempherol-3-d-galactoside, quercitrin, quer-
cetin, rutin, ursolic acid, senkirkine, doronine, β-sitosterol,
and stigmasterol [11, 12]. Our earlier study has demonstrat-
ed that γ-humulene (Figure 1(a)) induces cell apoptosis in
humancolorectalcancerHT29cellsthroughadeathreceptor
5- (DR5-) mediated pathway [11]. However, there is no
report addressing the possible anticolorectal cancer mech-
anism of methanolic ESE. The goal of this study was to
investigate the molecular mechanisms of apoptosis induced
by ESE in HCT 116 human colon cancer cells harboring the
wild-typep53gene.Basedonourresults,wesuggestthatESE
induces extrinsic and intrinsic apoptotic pathways in HCT
116 cells through a p53-mediated ATM/Fas signaling.
2.MaterialsandMethods
2.1. Chemicals and Reagents. Agarose, caﬀeine, DAPI (4,6-
diamidino-2-phenylindole dihydrochloride), DMSO (dim-
ethyl sulfoxide), γ-humulene, NAC (N-acetylcysteine), MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide), RNase A (ribonuclease-A), and Triton-X 100 were
purchased from Sigma-Aldrich Corp. (St. Louis, MO, USA).
RPMI-1640 medium, McCoy’s 5a medium, RPMI-1640 me-
dium, fetal bovine serum (FBS), L-glutamine, penicillin-
streptomycin, and H2DCF-DA were obtained from Invitro-
gen Life Technologies (Carlsbad, CA, USA). Ccaspase-3, -
8 and -9 colorimetric assay kits, Z-DEVD-FMK (a caspase-
3 inhibitor), Z-IETD-FMK (a caspase-8 inhibitor), and Z-
LEHD-FMK (a caspase-9 inhibitor) were purchased from
R&D Systems, Inc. (Minneapolis, MN, USA).
2.2. Plant Material and Preparation of Methanolic Emilia
sonchifolia Extract (ESE). ESE was provided by Dr. Yu-
Hsuan Lan (School of Pharmacy, China Medical University)
and prepared as described previously [10, 13]. Brieﬂy, this
plant was dried and powdered, and then extracted with light
petrol (60–80◦C) and ﬁltered with 70% methanol (Sigma-
Aldrich Corp.) at room temperature. The combined meth-
anolic extracts were ﬁltered and evaporated under reduced
pressure. The extract was resuspended in DMSO and used
for in vitro cytotoxicity and further experiments.
2.3. GC-MS Analysis of Methanolic ESE. The compositions
of methanolic ESE were analyzed by GC-MS (DSQ II
Single Quadrupole GC/MS, Thermoﬁsher Scientiﬁc, USA),
equipped with a 30m × 0.25mm × 0.25μmD B - 5 M S( A g -
ilent J&W Scientiﬁc). The GC oven temperature was pro-
grammed from 60◦C, held for 1min and raised to 250◦C
at 4◦C/min, held for 1min, then increased by 10◦C/min to
300◦C, and held for 1min to the end. The other parameters
were as follows: injection temperature, 100◦C; ion source
temperature, 250◦C; EI, 70eV; carrier gas, He at 1.5mL/min;
injection volume, 5μL; mass range, m/z 50–1050. The iden-
tiﬁcation of the major compound, γ-humulene, was based
on a comparison of MS spectra with an authentic standard
purchased from Sigma-Aldrich Corp.
2.4. Cell Culture. The human colorectal cancer cell line HCT
116 (wild-type p53), SW480 (p53 mutation), HT29 (p53
mutation), and human nonsmall cell lung cancer cell line
A549 (wild-type p53) and H1299 (null p53) were purchased
from the Food Industry Research and Development Institute
(Hsinchu, Taiwan). HCT 116 cells were cultured with 90%
McCoy’s 5a medium. The SW480, HT29, A549, and H1299
cells were cultured with 90% RPMI-1640 medium. All media
were supplemented with 10% FBS, 2mM L-glutamine and
100Units/mLpenicillinand100μg/mLstreptomycinundera
humidiﬁed 5%CO2,and 95% airat one atmosphereat 37◦C.
T h em e d i u mr e n e w a lw a sd o n ee v e r y2t o3d a y s[ 14].
2.5. MTT Cell Viability Assay and Morphological Observa-
tions. Cells seeded onto 96-well microplates at a density of
1 ×104 cells/100μL per well were incubated with ESE at the
concentrations of 0, 25, 50, 75, or 100μg/mL for a 24-hour
treatment.Themediumwasthenremoved,andthecellswere
incubated for 3h with 100μL of MTT solution (0.5mg/mL
MTT in PBS). The MTT-purple formazan productions
were dissolved in 0.1N isopropanol/hydrochloric acid (HCl)
and optical densities of the solutions were measured by
absorbance at 570nm in an ELISA plate reader. Cell viability
was expressed as the optical density ratio of the treatment
to the control (% of control) as described previously [15,
16]. For determining cell morphological experiment, cells
were examined and photographed using a phase-contrast
microscope as described elsewhere [16, 17].
2.6. Assessments of Apoptosis by TUNEL Assay and DNA
Gel Electrophoresis. Terminal deoxynucleotidyltransferase-
mediated dUTP-biotin nick end labeling (TUNEL) assay
was performed according to the manufacturer’s protocols
(In Situ Cell Death Detection Kit, Roche Diagnostics Corp.,
Indianapolis,IN,USA).Cells(1 ×106/well)wereplatedonto
six-well plates and exposed to 0, 25, 50, 75, or 100μg/mL
for 24h. After treatment, cells were collected and determined
as previously described [18, 19]. TUNEL-positive cells were
analyzed and quantitated using a FACSCalibur instrument
(BD Biosciences, San Jose, CA, USA) equipped with BD CellEvidence-Based Complementary and Alternative Medicine 3
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Figure 1: Representative GC-MS analysis of methanolic Emilia sonchifolia extract (ESE) and MS spectra of γ-humulene. The examination
conditions and monitoring wavelength of GC-MS analysis were described in the proﬁles indicated the standard compound (γ-humulene)
(a) and ESE (b), respectively.
Quest Pro software. Approximately 1 × 106 cells per well
were incubated without (control) or with 50μg/mL of ESE
for 24-hour exposure. Cells from each sample were collected
and the DNA was isolated for agarose gel electrophoresis as
previously described [19, 20]. After electrophoresis in a 1.5%
agarose gel containing ethidium bromide (EtBr, Invitrogen)
in 0.5x TBE buﬀer (AMRESCO Inc. Solon, OH, USA), the
DNA in gel was resolved with UV light and photographed
[19, 20].
2.7. Assays for Caspase-3, -8, and -9 Activities and Their
Speciﬁc Caspase Inhibitors Pretreatment for Viability and
TUNEL Assay. A density of 1 × 107 cells in 75cm2 ﬂask were
incubated with 50μg/mL of ESE for 0, 6, 12, and 24h and
the levels of caspase-3, -8, and -9 activities were assessed
according to the manufacturer’s protocol using caspase-3, -8,
and-9colorimetricassaykits(R&DSystems,Inc.).Aftercells
from each treatment were harvested and lysed, cell lysates
(50μg proteins) were incubated with caspase-3, -9, and -8
speciﬁcsubstrates(Ac-DEVD-pNA,Ac-LEHD-pNA,andAc-
IETD-pNA, resp.) from these kits in 96-well ﬂat bottom
microplates for 1h at 37◦C. The caspases activities were
determined by measuring the release of pNA at OD405 using
an ELISA reader (Anthos 2001, anthos Labtech Instruments,
Salzburg, Austria) as previously described [16, 20]. For
viability and TUNEL assay, cells were pretreated with or
without the caspase-3 inhibitor (10μM; Z-DEVD-FMK),
caspase-8 inhibitor (10μM; Z-IETD-FMK) and caspase-94 Evidence-Based Complementary and Alternative Medicine
inhibitor (10μM; Z-LEHD-FMK) for 1h before exposure
to 50μg/mL of ESE for 24h. Cells were harvested for de-
termining the cell viability by MTT assay and apoptosis by
TUNEL assay as described above [15, 16].
2.8.Real-TimePCRofFas. Cellswereculturedin75-Tﬂasks.
ESE (50μg/mL) was added to cells for 0, 6, and 12h. Cells
were harvested and total RNA was extracted with the
Qiagen RNeasy Mini Kit (Qiagen, Valencia, CA, USA). RNA
sampleswerereverse-transcribedat42◦CwithHighCapacity
cDNA Reverse Transcription Kit for 30min according to the
protocol of the supplier (Applied Biosystems, Foster City,
CA, USA). Quantitative PCR conditions were as follows:
2min at 50 ◦C, 10min at 95◦C, and 40 cycles of 15s at
95◦C; 1min at 60◦C using 1μL of the cDNA reverse-
transcribed as described above, 2X SYBR Green PCR Mas-
ter Mix (Applied Biosystems) and 200nM forward and
reverse primers (homo Fas-F: GCAACACCAAATGCAA-
GAAA; homo Fas-R: GGATTCCAGATTCAGGGTCA; homo
GAPDH-F ACACCCACTCCTCCACCTTT; homo GAPDH-
R TAGCCAAATTCGTTGTCATACC). Applied Biosystems
7300 real-time PCR system was used for each assay in
triplicate,andexpressionfoldchangeswerederivedusingthe
comparative CT method as previously described [17, 21].
2.9. Determination of Levels of Proteins Associated with
Apoptotic Death and p53/Fas Signaling by Western Blotting.
Cells at a density of 1 × 107 cells in 75cm2 ﬂask were treated
with 50μg/mL of ESE for indicated intervals of time (0, 6,
12, and 24h or 0, 2, and 4h, resp.). Cells at the end of
each treatment period were harvested, and isolated total
proteins, mitochondrial and cytosolic proteins, and protein
quantiﬁcation were as described previously [22, 23]. The
lysates from each sample were centrifuged at 13000×gf o r
10min and the protein concentration in the supernatant was
determined with a PIERCE BCA protein assay kit (Thermo
Fisher Scientiﬁc Inc. Rockford, IL, USA) as previously
described [22, 24]. Equal amounts (40μg) from each sample
of protein lysate were run on 10–12% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The
iBotTM Dry Blotting System (Invitrogen) was used to
electrotransferred to a PVDF membrane and thereafter the
blot was blocked with 5% nonfat dry milk and 0.05% Tween
20 in PBS at pH 7.4 at room temperature for 1h. After
blocking, the membranes were incubated with anti-caspase-
3, anti-caspase-8, anti-caspase-9, anticytochrome c (Cell
Signaling Technology, Danvers, MA, USA), anti-Bcl-2, anti-
Bax, anti-Bid, anti-PUMA, anti-Fas, anti-FasL, anti-DR4,
anti-DR5, anti-ATM, anti-p-ATMSer1981 (Santa Cruz Bio-
technology, Inc., Santa Cruz, CA, USA), anti-p53 and
p-p53Ser15 (Abcam, Cambridge, U.K.) antibodies at 4◦C
overnight. These membranes were then incubated with
horseradish peroxidase- (HRP-) conjugated goat anti-mouse
or anti-rabbit IgG secondary antibodies (Millipore, Billerica,
MA, USA) for 2h at room temperature with gentle shaking.
After washing, bands were visualized by Immobilon Western
chemiluminescent HRP substrate (ECL) kit (Millipore)
according to the manufacturer’s instructions followed by
development on Kodak Bio-MAX MR ﬁlm (Eastman Kodak,
Rochester, NY, USA). The relative abundance of each band
was quantiﬁed using ImageJ software (version 1.43, NIH,
USA) for Windows [17, 25]. Blots were reported with actin
antibody as a loading control.
2.10. Immunoﬂuorescence Staining and Confocal Laser Scan-
ning Microscopy. Cells (5 × 104 cells/well) were placed on
4 - w e l lc h a m b e rs l i d e sb e f o r eb e i n gt r e a t e dw i t h5 0 μg/mL
of ESE for 24h. Cells were then ﬁxed in 3% formaldehyde
(Sigma-Aldrich Corp.) for 15min, permeabilized with 0.1%
Triton-X 100 in PBS for 1h with blocking of non-speciﬁc
binding sites using 2% bovine serum albumin (BSA) as
described elsewhere [19, 26]. These ﬁxed cells were stained
with primary antibodies to cleaved caspase-3 (1:100 dilu-
tion, Cell Signaling Technology) overnight, which was de-
tectedusingaFITC-conjugatedgoatanti-mouseIgGsecond-
ary antibody (1:100 dilution, green ﬂuorescence; Millipore)
followed by nuclei counterstaining using and PI (Sigma-
Aldrich Corp.) (red ﬂuorescence). Photomicrographs were
obtained using a Leica TCS SP2 Confocal Spectral Micro-
scope [26, 27].
2.11. Measurement of Reactive Oxygen Species (ROS) Produc-
tion and N-Acetylcysteine, Caﬀeine Pretreatment for Viability.
Cells at a density of 2 × 105 cells/well were plated onto 12-
well plates and treated with 50μg/mL of ESE for 0, 2, and
4h followed the determinations of the changes in ROS level.
Cells were harvested from each treatment, resuspended in
500μLo fH 2DCF-DA (5μM) for ROS (hydrogen peroxide;
H2O2)a t3 7 ◦C for 30min. Consequently, cells were immedi-
a t e l ya n a l y z e db yﬂ o wc y t o m e t r ya sd e s c r i b e de l s e w h e r e[ 28,
29].Allﬂuorescenceintensitieswereobtainedfromthemean
intensity of the histogram constructed from approximately
10,000 cells using BD CellQuest Pro software. For viability
assay, cells were pretreated with or without the 10mM N-
acetylcysteine (NAC, an antioxidant) or 1mM caﬀeine (an
ATM kinase inhibitor) for 1h before exposure to 50μg/mL
of ESE for 24h. Cells were harvested for determining the cell
viability by MTT assay as described above [15, 16].
2.12. Small Interfering RNA Transfection. Cells at a density
of 2 × 105 cells/well were seeded in 6-well plates and grown
to 70% conﬂuence. p53 siRNA (100nM, Santa Cruz Bio-
technology, Inc.) or control siRNA was transfected using
Lipofectamine 2000 (Invitrogen) for 12h according to the
manufacturer’s guideline [8]. After being transfected with
p53 siRNA, cells were seeded and treated with 50μg/mL of
ESE for 24-h exposure. Cells were harvested for determining
the protein abundance of p53, Fas, PUMA, caspase-8, and
caspase-3 by Western blotting and analysis for cell viability
using MTT assay and apoptosis by TUNEL as described
above [15, 16].
2.13. Statistical Analysis. A l ld a t aw e r ee x p r e s s e da sm e a n±
SD from at least three separate experiments. Statistical
calculations of the data were obtained using Student’s t-testEvidence-Based Complementary and Alternative Medicine 5
with signiﬁcance value of ∗∗∗P<0.001, which is considered
signiﬁcantly.
3. Results
3.1. Characterization of Methanolic Emilia sonchifolia Extract
(ESE). Results shown in Figure 1 indicated that major com-
position of methanolic Emilia sonchifolia extract (ESE) was
“γ-humulene” (Figure 1(a)) and the content was 63.86%
(Figure 1(b)) based on peak area integrated by Ther-
moXcaliburTM data analysis program.
3.2. ESE Reduced Cell Viability and Induced Apoptotic Mor-
phological Changes in HCT 116 Cells. To investigate the
cytotoxic responses of the ESE in HCT 116 cells, cells were
exposed to various concentrations of ESE (0, 25, 50, 75 or
100μg/mL)for24h,anddeterminedandanalyzedtheviabil-
ity using the MTT assay. Results shown in Figure 2(a) indi-
cated that ESE decreased the viable HCT 116 cells and this
eﬀect was in a concentration-dependent manner. Figure 2(b)
indicates that ESE-treated HCT 116 cells occurred rounding
and shrinking, which exhibited the morphological changes
when cell apoptosis. Treatment with ESE in 50μg/mL
concentration, which is a close to half maximal inhibitory
concentration (IC50) for 24h, was used for further experi-
ments in this study.
3.3. ESE Induced Apoptosis and DNA Fragmentation in HCT
116 Cells. To test whether ESE induced the decrease of cell
viability and cytotoxicity contributes to apoptotic death in
HCT 116 cells in vitro. Cells were incubated with 0, 25, 50,
75, or 100μg/mL of ESE for 24h and then determined using
TUNEL assay. Our data revealed that apoptotic evidence
in ESE-treated HCT 116 cells concentration dependently
increased and TUNEL-positive cells were from 14% to 63%
populations after ESE treatment at 25–100μg/mL when
compared to the control (0μg/mL) group (P<0.05)
(Figure 2(c)). Moreover, DNA gel electrophoresis conﬁrmed
that ESE induced apoptosis and DNA ladders in HCT 116
cells after 50μg/mL of ESE exposure (Figure 2(d)).
3.4. ESE Enhanced the Activities of Caspase-3, -8 and -9 in
HCT 116 Cells. The observation of apoptotic death induced
by ESE raised the possibility that activations of caspase
cascades were required for examining the treated HCT
116 cells in vitro. Thus, we next examined the proteolytic
activation of caspase cascades in ESE-treated HCT 116
cells and our results indicated that ESE stimulated caspase-
3, caspase-8, and caspase-9 activities in a time-dependent
eﬀect (Figure 3(a)). The protein levels of pro-caspase-3,
pro-caspase-8, and pro-caspase-9 were downregulated in
HCT 116 cells after ESE exposure (Figure 3(b)). In addi-
tion, the result in Figure 3(c) from confocal microscopy
indicated ESE stimulated the translocation of caspase-3
traﬃcking to the nuclei when compared to the control
sample. Importantly, pretreatment with speciﬁc inhibitors
of caspase-3 inhibitor (Z-DEVD-FMK), caspase-8 inhibitor
(Z-IETD-FMK), and caspase-9 inhibitor (Z-LEHD-FMK),
respectively, signiﬁcantly prevented against the ESE-induced
cell growth inhibition (Figure 3(d)) and apoptosis in HCT
116 cells (Figure 3(e)).
3.5. ESE-Triggered Apoptosis in Mediated Mitochondria- and
Death-Receptor-Dependent Signaling in HCT 116 Cells. To
assess the alterations in apoptosis-related protein levels in
ESE-treated HCT 116 cells, we administered ESE at the
concentration of 50μg/mL for 0, 6, 12, and 24h in HCT 116
cells and then evaluated the protein levels by Western blot
analysis. Figure 4(a) shows that ESE promoted a decrease
of Bcl-2 level (an antiapoptotic protein) and the increases
of proapoptotic protein levels of Bax and PUMA in HCT
116 cells. Also, treatment of ESE showed that the level of
Bid was downregulated in HCT 116 cells (Figure 4(a)). As
shown in Figure 4(b), ESE enhanced the death receptor
pathway-associated protein levels (Fas, DR4 and DR5) in
HCT 116 cells. Alternatively, the level of cytochrome c from
cytosolic fraction is upregulated and from mitochondrial
fraction is downregulated in ESE-treated HCT 116 cells
(Figure 4(c)). Collectively, these results suggest that both
intrinsic (mitochondria) and extrinsic (death-receptor-)
dependent pathways contributed to ESE-provoked apoptotic
death in HCT 116 cells.
3.6. ESE Increased ROS Production and Stimulated
ATM/p53/Fas Signaling in HCT 116 Cells. Results shown in
Figure 5(a) revealed that ESE promoted the level of intra-
cellular ROS production (2h treatment: 81.26 ± 2.39%; 4h
treatment:90.34±4.18%)inHCT116cellsbyﬂowcytometry
and a speciﬁc ﬂuorescent probe, H2DCFDA for determining
ROS level. Cells pretreated with N-acetylcysteine (NAC,
an antioxidant) and caﬀeine (an ATM kinase inhibitor)
signiﬁcantly reduced ESE-induced growth inhibition eﬀect
(Figure 5(b)). Previous studies have stated that p53 gene
and its phosphorylation at the Ser15 interacted Fas/CD95
activation when cell apoptosis occur [7, 8, 30]. To elucidate
the crucial roles of ATM, p53 and Fas in HCT 116 cells after
treatment with ESE, the protein levels of ATM, p-ATMSer1981,
p53, and p-p53Ser15 expression were investigated by Western
blot analysis. Our results showed that ESE increased the
protein levels of ATM, p-ATMSer1981, p53 and p-p53Ser15 in
HCT 116 cells as can be seen in Figure 5(b). Our further
study investigated if p53 aﬀects the Fas expression in ESE-
treated HCT 116 cells. We hypothesized that ESE induces
apoptosis through the increase of Fas/CD95 by p53-depend-
ent transcriptional activation. real-time PCR analysis was
performed to determine whether the induction of Fas/CD95
protein level by ESE was due to increased the level of mRNA.
As shown in Figure 5(d), the 6 and 12h treatment of HCT
116 cells with ESE (50μg/mL) led to an increase in mRNA
levels of Fas/CD95. Our results indicate that ESE increased
the protein level of Fas/CD95 through the p53-dependent
regulation of transcription levels.
Therefore, our results showed that the induction of p53,
Fas, PUMA, cleaved caspase-8, and cleaved caspase-3 due
to ESE treatment was correlated with the decrease in p53,
Fas, PUMA, cleaved caspase-8, and cleaved caspase-3 protein
levels by the transfection with p53 siRNA in HCT 1166 Evidence-Based Complementary and Alternative Medicine
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Figure 2: ESE reduced cell viability and induced morphological changes, apoptosis, and DNA fragmentation in HCT 116 cells. (a) Cells
were exposed to various concentrations of ESE (0, 25, 50, 75, or 100μg/mL) for 24h and determined and analyzed the viability using the
MTT assay. (b) HCT 116 cells in response to 25, 50, and 100μg/mL of ESE for 24-h exposure were photographed at 200x magniﬁcation and
showed apoptotic morphological changes. (c) Cells were cultured with 0, 25, 50, 75, or 100μg/mL of ESE for 24h for determining apoptotic
cells by TUNEL assay and ﬂow cytometric analysis. (d) Treatment with ESE (50μg/mL) in HCT 116 cells shows DNA ladders by DNA gel
electrophoresis. The values presented are the mean ± S.D. (n = 3) from three independent experiments. ∗∗∗P<0.001 shows a signiﬁcant
diﬀerent when compared to control (0h) sample.
cells (Figure 6(a)). We found that ESE-reduced viability in
HCT 116 cells was nearly enhanced after using p53 siRNA
compared to the ESE alone sample as shown in Figure 6(b).
We also found that ESE induced apoptosis in HCT 116 cells
was nearly prevented after using p53 siRNA compared to the
ESE alone sample as shown in Figure 6(c). Taken together,
these results suggest that p53 activation is an important
factor in ESE-induced apoptosis of HCT 116 cells, which is
mediated through ROS productions (oxidative stress) and
ATM/p53/Fas-dependent signaling pathways.
4. Discussion
Phytochemicals aﬀect intracellular targets, and this charac-
teristics often makes desirable on tumor cells as chemo-
preventive or chemotherapeutic agents against cancer [31].Evidence-Based Complementary and Alternative Medicine 7
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Figure 3: ESE aﬀected the activities and protein levels of caspase-3, -8, and -9 in HCT 116 cells. Cells were treated with 50μg/mL of ESE
for 6, 12, and 24h. (a) ESE stimulated the activities of caspase-3, caspase-8, and caspase-9 in HCT cells as described in Section 2.T h e
values presented are the mean ± S.D. (n = 3) from three independent experiments. ∗∗∗P<0.001 indicates a signiﬁcant diﬀerent when
compared to control (0 h) sample. (b) The total proteins were harvested from ESE (50μg/mL) treated HCT 116 cells for 0, 6, 12, and 24
h and determined the protein levels of pro-caspase-3, pro-caspase-8, and pro-caspase-9 by Western blotting. Actin was used as a loading
control. (c) ESE stimulated the translocation of caspase-3 traﬃcking to nuclei in HCT 116 cells by confocal laser scanning microscope as
describedinSection 2.Cellswerepre-incubatedwithorwithoutspeciﬁcinhibitorsofcaspase-3(Z-DEVD-FMK),caspase-8(Z-IETD-FMK),
andcaspase-9(Z-LEHD-FMK),respectively,andthentreatedwithESE-(50μg/mL)for24h.ThecellularviabilitywasassessedbyMTTassay
(d) and apoptotic cells were assessed by TUNEL assay and ﬂow cytometric analysis (e). The values presented are the mean ± S.D. (n = 3)
from three independent experiments. ∗∗∗P < 0.001 shows a signiﬁcant diﬀerent when compared to ESE treatment.8 Evidence-Based Complementary and Alternative Medicine
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Figure 4: ESE altered the protein abundance-associated with mitochondria- and death-receptor-dependent apoptotic signaling in HCT 116
cells. Cells were treated with ESE (50μg/mL) for 0, 6, 12, 24h, and total protein, cytosolic, and mitochondrial lysates were prepared and
subjected to Western blotting analysis. The membranes were incubated with (a) anti-Bcl-2, anti-Bax, anti-Bid and anti-PUMA antibodies;
(b) anti-Fas, anti-FasL, anti-DR4 and anti-DR5 antibodies; (c) anticytochrome c antibody. The blot was also probed with anti-Actin and
anti-Complex V antibodies to conﬁrm equal loading of samples. Each band was quantiﬁed using ImageJ software.
The previous study showed that ESE inhibited lymphoma,
Ehrlich ascites carcinoma, and mouse lung L-929 ﬁbroblast
cells, and it is important that ESE is not toxic to normal
cells in vitro [10]. In vivo study also indicated that oral
administration of the ESE (100mg/kg body weight) to mice
increased the life span and reduced the solid tumor volume
of tumor-bearing mice [10–12]. In the present study, we
ﬁrstly demonstrated that ESE reduced cell proliferation in
HCT 116 human colorectal cancer cells through induction
of cell apoptosis. Additionally, it had low toxicity to human
normal skin ﬁbroblast Detroid 551 cells (IC50 > 200μg/mL)
in vitro (data not shown). The IC50 for 24h treatment of
ESE in HCT 116 and HT29 cells were 50.54 ± 2.28 and
88.54 ± 4.01μg/mL, respectively (Table 1). Because p53 is
frequently expressed in colorectal cancer, new agents that
preferentially kill p53-expressing cells are highly desirable
chemotherapeutic agents. To investigate the selective toxicity
of ESE in diﬀerent p53 gene expression cell lines, we demon-
strated three human colorectal cancer cell lines (HCT 116,
SW480, and HT29) and two lung cancer cell lines (A549 and
H1299) [32–35].
TheIC50 values calculatedfrom these results arereported
in Table 1; SW480, HT29, and A549cell lines, which carries a
mutant form of the p53 gene, are signiﬁcantly low cytotoxic
action of ESE than the HCT116cell line, carrying a wild-
type p53 gene. However, H1299 cells are 2-fold IC50 values
to ESE than HCT116 cells (Table 1). In comparison to the
mutant p53cell lines or null p53cell line, a greater cytotoxicEvidence-Based Complementary and Alternative Medicine 9
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Figure 5: ESE increased ROS production and contributed to p53-correlated ATM/Fas apoptotic signaling in HCT 116 cells. (a) Treatment
with ESE (50μg/mL) for the indicated times (0, 2, and 4h) was subjected to ROS productions by ﬂow cytometry as described in Section 2.
(b) Pretreatment with NAC (10mM, a scavenger of ROS), or caﬀeine (1mM, an inhibitor of ATM) in ESE-treated HCT 116 cells restored
the cell viability by MTT assay. The values presented are the mean ± S.D. (n = 3) from three independent experiments. ∗∗∗P < 0.001 shows
a signiﬁcant diﬀerent when compared to ESE treatment. (c) ESE elevated the protein levels of ATM, phosphorylated ATM (Ser1981), p53,
phosphorylation, and p53 (Ser15) by Western blotting. (d) Eﬀects of ESE on Fas mRNA level in HCT 116 cells, and the total RNA was
extracted from each treatment of ESE (50μg/mL) on HCT 116 cells for 0, 6, and 12h. RNA samples were reverse transcribed into cDNA
and quantiﬁed with real-time PCR as described in Section 2. The ratios of Fas mRNA/GAPDH are presented. The values presented are the
mean ±S.D.(n =3)fromthreeindependentexperiments. ∗∗∗P <0.001showsasigniﬁcantdiﬀerentwhencomparedtocontrol(0h)sample.
eﬀect was found in the wild-type p53cell lines. The results
suggested that ESE preferentially induced more cytotoxic
eﬀect in the wild-type p53 lines than in the mutant or null
p53 colorectal cancer cells. The reasons for the diﬀerences
in sensitivities in IC50 of those cell lines may be due to the
intrinsic diﬀerent p53 gene in diﬀerent types of cell lines.
The p53 in SW480 and HT29 cells has been shown to be
a mutated gene with a mutation at codon 273 and that in
HCT 116 cells is future to be functional without mutation
[36]. It is reported that p53 is a mediator of chemotherapy-
induced cell death, resulting from ROS productions which
is activated by chemotherapeutic agents [37]. Many studies
reported that cisplatin did not signiﬁcantly increase apop-
tosis in p53-mutant cells, but a signiﬁcant increase in the
apoptotic index was observed in wild type p53 cells which
correlates with increased p53 protein level [38–40]. Our
results suggest that ESE induced apoptosis in HCT 116 cells
through p53-mediated signaling. In this study, our results10 Evidence-Based Complementary and Alternative Medicine
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Figure 6: ESE-aﬀected cytotoxicity and apoptosis is mediated through alterations of p53 downstream signals in p53 siRNA-transfected HCT
116 cells. (a) The p53 siRNA or control siRNA-transfected HCT 116 cells were treated with ESE (50μg/mL) for 12h, and total protein was
preparedandsubjectedtoWesternblottinganalysis.Themembraneswereincubatedwithanti-p53,anti-Fas,anti-PUMA,anticaspase-8and,
anti-caspase-3 antibodies. The blot was also probed with anti-Actin antibody to conﬁrm equal loading of samples. Each band was quantiﬁed
using ImageJ software. The p53 siRNA or control siRNA-transfected HCT 116 cells were treated with ESE (50μg/mL) for 24h, cell viability
was determined by MTT assay (b) and apoptotic cells were assessed by TUNEL assayand ﬂow cytometric analysis (c). The values presented
are the mean ± S.D. (n = 3) from three independent experiments. ∗∗∗P < 0.001 shows a signiﬁcant diﬀerent when compared to control
sample.
demonstrated that γ-humulene is the major constituent in
Emilia sonchifolia b yG C / M Sa n a l y s i s( Figure 1). Recently, we
ﬁrst demonstrated that γ-humulene has anticancer activity
by stimulating the clustering of DR4/DR5 and associated
FADD protein levels, leading to caspase-8 and caspase-3
activation, and then induction of apoptosis in HT29 cells
[11]. Correctively, our results suggest that γ-humulene is the
major bioactive compound in ESE.
Apoptosis is an intracellular suicide program possessing
morphologic change and biochemical response. In the
present study, we showed that ESE reduced the cell viability
in HCT 116 cells in a concentration-dependent manner
(Figure 2(a))andtriggeredapoptoticmorphologicalchanges
(Figure 2(b)). ESE induced DNA condensation and frag-
mentation by DNA gel electrophoresis and TUNEL staining
(Figures 2(c) and 2(d)). Two major apoptotic pathways
have been described the extrinsic (death receptor medi-
ated) and the intrinsic pathway (mitochondria mediated)
[41]. The intrinsic apoptotic pathway aﬀected mitochon-
drial permeability, releases cytochrome c,A p a f - 1 ,E n d oG ,
and pro-caspase-9 proteins from mitochondria to cytosol,
leading to activation of caspase-9. The extrinsic apoptoticEvidence-Based Complementary and Alternative Medicine 11
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Figure 7: A proposed working model for the action and possible signaling pathways of ESE on HCT 116 human colorectal cancer cells.
ESE induces apoptosis through both extrinsic and intrinsic apoptotic pathways, resulting from p53-mediated ATM/Fas signaling, which
counteracts the induction of apoptotic death in HCT 116 cells (see text for details).
Table 1: The IC50 values for 24hour-treatment of ESE in diﬀerent
p53 gene expression cell lines (mean ± S.D. of three independent
experiments).
Cell line p53 gene
expression IC50 (μg/mL)
HCT
116
Human colorectal
cancer cell lines
Wild-type 50.54 ±2.28
SW480 Mutation
(Arg273 →His) 79.62 ±6.05
HT29 Mutation
(Arg273 →His) 88.54 ±4.01
A549 Human nonsmall cell
lung cancer cell lines
Wild-type 53.69 ±3.17
H1299 Null 121.36 ±5.33
pathways originateing at membrane death receptors include
Fas/CD95, DR4 and DR5 and then inﬂuence the intracellular
apoptotic adaptor FADD protein and proximal caspase-8
as well as distal executioner caspases [41–43]. Our results
demonstrated that ESE signiﬁcantly increased activities of
caspase-3, caspase-8, and caspase-9 (Figure 3(a))a f t e r6t o
24 h treatment, and pretreatment with speciﬁc inhibitors of
caspase-3, -8, and -9, respectively, led to increased viable
cells in ESE treatment (Figure 3(c)). On the other hand,
pretreatment of cells with speciﬁc inhibitors to caspase-3, -8,
and-9signiﬁcantlypreventedtheESE-inducedcellapoptosis
(Figure 3(e)). Our results suggest that both of extrinsic and
intrinsic apoptotic pathways may be involved in the ESE-
provoked apoptotic death in HCT 116 cells.
Recently, many studies have shown that p53-inducible
proapoptotic genes trigger apoptosis through both extrinsic
and intrinsic apoptotic pathways [44–46]. In this study,
we demonstrated that the ESE signiﬁcantly increased ROS
production (Figure 5(a)), the protein levels of PUMA
(Figure 4(a)), Fas (Figure 4(b)), ATM, p-ATMSer1981, p53, p-
p53Ser15,and in HCT 116 cells (Figure 5(b)). In addition,
knockdown of p53 expression by p53 siRNA signiﬁcantly
inhibited the protein level of Fas/CD95, PUMA, cleaved
caspase-8 and cleaved caspase-3 (Figure 6(a)), cell growth-
inhibitory eﬀects (Figure 6(b)), and apoptosis (Figure 6(c))
after treatment with ESE in HCT 116 cells. According to
our results, we suggest that p53 might be involved in ESE
upregulatedFas-mediatedextrinsicapoptoticsignalingpath-
ways.
Inconclusion,themolecularsignalingpathwaysaresum-
marized in Figure 7. The present study revealed that ESE
(i) decreased the percentage of viable cells; (ii) induced
apoptotic morphological changes and DNA fragmentation;
(iii) upregulated the protein levels and activated the levels
of caspase-3, caspase-8, and caspase-9; (iv) increased the
ROS production and upregulated the protein levels of ATM,
p-ATMSer1981, p53 and p-p53Ser15; (V) stimulated the p53
downstream protein levels of Fas/CD95 and PUMA. Our
results suggest that ESE warrants further development as
a colorectal cancer prevention or therapeutic agents in the
future.12 Evidence-Based Complementary and Alternative Medicine
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